Universal Beteiligungs und Servicegesellschaft mbH Boosts Stake in Elanco Animal Health Incorporated $ELAN

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Elanco by 33.1% in Q4 to 402,899 shares, worth about $9.13 million (roughly 0.08% of the company).
• Other large institutions — including UBS, Goldman Sachs, Dimensional and Jupiter — also materially increased positions, leaving institutional ownership at about 97.48%.
• Elanco beat recent quarterly EPS and revenue estimates, set FY2026 guidance at $1.00–$1.06 EPS, and holds a consensus "Moderate Buy" analyst rating with an average price target of $27.90.

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 33.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 402,899 shares of the company's stock after purchasing an additional 100,095 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.08% of Elanco Animal Health worth $9,126,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of ELAN. UBS Group AG grew its holdings in Elanco Animal Health by 56.7% in the third quarter. UBS Group AG now owns 16,468,148 shares of the company's stock valued at $331,669,000 after purchasing an additional 5,961,457 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after buying an additional 2,445,872 shares during the period. Bowen Hanes & Co. Inc. acquired a new position in shares of Elanco Animal Health during the 3rd quarter worth approximately $47,626,000. Dimensional Fund Advisors LP lifted its position in shares of Elanco Animal Health by 8.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company's stock valued at $497,610,000 after buying an additional 1,962,276 shares in the last quarter. Finally, Jupiter Asset Management Ltd. lifted its position in shares of Elanco Animal Health by 98.8% during the 3rd quarter. Jupiter Asset Management Ltd. now owns 3,716,849 shares of the company's stock valued at $74,857,000 after buying an additional 1,846,907 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Stock Up 0.0%

Shares of ELAN opened at $22.76 on Monday. The firm has a market cap of $11.31 billion, a P/E ratio of -47.41, a price-to-earnings-growth ratio of 2.90 and a beta of 1.88. Elanco Animal Health Incorporated has a 12-month low of $9.26 and a 12-month high of $27.72. The company's 50-day moving average price is $24.09 and its 200 day moving average price is $23.21. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the firm posted $0.14 earnings per share. Elanco Animal Health's revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.03 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Citigroup started coverage on shares of Elanco Animal Health in a report on Wednesday, April 15th. They issued a "buy" rating and a $30.00 price target for the company. Morgan Stanley raised their price target on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 25th. UBS Group reaffirmed a "buy" rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Piper Sandler upgraded Elanco Animal Health from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. boosted their price target on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $27.90.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.